Prognostic Factors of Disease-Free Survival after Thyroidectomy in 170 Young Patients with a RET Germline Mutation: A Multicenter Study of the Groupe Français d'Etude des Tumeurs Endocrines

2011 ◽  
Vol 2011 ◽  
pp. 130-131
Author(s):  
M. Schott
2015 ◽  
Vol 55 (1-2) ◽  
pp. 12-23 ◽  
Author(s):  
In-Hwan Kim ◽  
Sang-Gyu Kwak ◽  
Hyun-Dong Chae

Background/Purpose: Gastric gastrointestinal stromal tumors (GISTs) have a highly variable clinical course, and recurrent disease sometimes develops despite curative surgery. This study was undertaken to investigate the surgical role in treating gastric GISTs and evaluate the clinicopathological features of a large series of patients who underwent curative resection for gastric GISTs to clarify which features were independent prognostic factors. Methods: The clinicopathological data of 406 patients with gastric GISTs who underwent curative resection at 4 university hospitals in Daegu, South Korea, from March 1998 to March 2012 were reviewed. All cases were confirmed as gastric GISTs by immunohistochemical staining, in which CD117 or CD34 was positive. Clinical follow-up was performed periodically, and disease-free survival rates were retrospectively investigated using the medical records. Results: The mean follow-up period was 42.9 months (range: 2-166). There were 11 recurrent patients (2.7%). Due to the small number of recurrences, age, sex and location were controlled using propensity score matching before performing any statistical analysis. Tumor size, mitotic count, NIH classification, and cellularity were judged to be independent prognostic factors for recurrence by univariate analysis. In a multivariate analysis, tumor size and mitotic count were significantly and independently related to recurrence, and tumor size was determined to be the most important prognostic factor for recurrence after curative resection (hazard ratio: 1.204; p < 0.01). Conclusions: The results of this multicenter study demonstrate that disease-free survival rates are good. Tumor size was disclosed as the most important factor for recurrence in gastric GIST patients who underwent radical resection.


2020 ◽  
Author(s):  
panquan luo ◽  
lixiang zhang ◽  
lei chen ◽  
gang wang ◽  
hai zhu ◽  
...  

Abstract Background Hepatocellular carcinoma (HCC) is a primary malignancy of the hepatocyte with high risk of invasion, metastasis and poor prognosis, which leads to a high mortality rate in recent years. This study aims to investigate the independent prognosis factors of DFS(disease free survival) in hepatocellular carcinoma patients after radical hepatectomy.Methods This study retrospectively analyzed 358 patients admitted to the 1st Affiliated Hospital of Anhui Medical College from December 2009 to December 2014. Categorical variables were analyzed by chi-square test. The survival curve was plotted by kaplan-meier method and tested by log-rank method. Univariate and multivariate Cox regression analyses were performed to determine the prognostic factors.Results Among the 344 patients with liver cancer, 298 cases (86.63%) are young patients (< 70 years), and 46 cases (13.37%) were elderly patients (≥ 70 years). There were no significant difference in gender, smoking history, alcohol consumption history, Body Mass Index (BMI), number of cancer nodules, tumor diameter, differentiation degree and TNM stage between the young and elderly groups (P > 0.05). However, history of hepatitis B and liver cirrhosis were more common in young patients than elderly (P=0.017, P༝0.000). The Kaplan-Meier curves indicated that elderly patients (higher than 70 years), TNM I-II stage and no history of hepatitis B had longer DFS. The univariate and multivariate analyses showed that age, TNM stage, History of hepatitis B were the independent factors for DFS.Conclusions Our findings suggested that age, TNM stage, history of hepatitis B were independent factors for predicting DFS of primary hepatocellular carcinoma patients. Patients older than 70 years had a better prognosis than young patients. Patients with early TNM stage and no history of hepatitis B had longer DFS.


2020 ◽  
Vol 59 (7) ◽  
pp. 809-817
Author(s):  
Marloes Duijm ◽  
Noëlle C. van der Voort van Zyp ◽  
Patrick V. Granton ◽  
Paul van de Vaart ◽  
Mirjam E. Mast ◽  
...  

2008 ◽  
Vol 179 (4S) ◽  
pp. 193-193
Author(s):  
Michele Lodde ◽  
Helene Hovington ◽  
Francois Harel ◽  
Michael J Harris ◽  
David P Wood ◽  
...  

2020 ◽  
Vol 28 (3) ◽  
pp. 496-504
Author(s):  
Muhammet Sayan

Background: This study aims to identify the prognostic factors in Stage IIIA non-small cell lung cancer and to investigate whether there was a significant difference in terms of overall survival and disease-free survival among the subgroups belonging to this disease stage. Methods: Between January 2010 and December 2018, a total of 144 patients (125 males, 19 females; median age 60 years; range, 41 to 80 years) who were operated for non-small cell lung cancer in our clinic and whose pathological stage was reported as IIIA were retrospectively analyzed. Data including demographic and clinical characteristics of the patients, histopathological diagnosis, the standardized uptake value of the mass on positron emission tomography-computed tomography, tumor diameter, type of surgery, lymph node metastasis status, visceral pleural invasion, and overall and disease-free survival rates were recorded. Results: The median survival was 39 (range, 27.8 to 46.1) months and the five-year overall survival rate was 28%. The mean tumor diameter was 4.3±2.7 cm. The median disease-free survival was 37 (range, 28.1 to 48.6) months and the five-year disease-free survival rate was 26.9%. In the multivariate analysis, overall survival and disease-free survival in T2N2M0 subgroup were significantly worse than the other subgroups. The other poor prognostic factors of survival were the standardized uptake value of the tumor, pneumonectomy, and histopathological subtypes other than squamous cell carcinoma and adenocarcinoma. Parietal pleural invasion was significantly associated with worse disease-free survival rates. Conclusion: Our results showed that there may be significant survival differences between subgroups created by tumor histopathology, lymph node invasion and the type of surgery in a heterogeneous lung cancer stage.


2014 ◽  
Vol 25 ◽  
pp. iv323
Author(s):  
Y. Poryvaev ◽  
G.A. Nerodo ◽  
V. Ivanova ◽  
E. Nerodo

2013 ◽  
Vol 23 (7) ◽  
pp. 1303-1310 ◽  
Author(s):  
Dae Woo Lee ◽  
Keun Ho Lee ◽  
Jung Won Lee ◽  
Sung Taek Park ◽  
Jong Sup Park ◽  
...  

ObjectiveThe primary objective of the study was to compare the survival rate of patients who had received neoadjuvant chemotherapy with that of patients who had received radiation therapy for stage IIB cervical cancer. The secondary objective was to analyze the effect of neoadjuvant chemotherapy on pathological prognostic factors.Materials and MethodsWe retrospectively reviewed the medical records of patients who had received therapy for stage IIB cervical cancer. Based on the primary therapy, 192 patients were divided into 2 groups; patients in the neoadjuvant chemotherapy group (n =103) underwent a type III radical hysterectomy after completion of the neoadjuvant chemotherapy. Patients in the other group (n = 89) were treated with radiation alone or a combination of chemotherapy and radiotherapy.ResultsAfter neoadjuvant chemotherapy, the level of squamous cell carcinoma antigen, tumor size, lymph node involvement, and parametrium involvement were significantly decreased. However, 90.3% of the patients who had received neoadjuvant chemotherapy needed to have adjuvant therapy after radical surgery because of poor pathological prognostic factors. The rate of disease-free survival did not differ significantly between the 2 groups. However, the overall survival rate was significantly lower in the neoadjuvant chemotherapy group for patients who were 60 years or older (P = 0.03). The rates of disease-free survival and overall survival for patients who had a good (complete or partial) response to the neoadjuvant chemotherapy were not significantly higher than the rates for patients in the radiation therapy group.ConclusionsAlthough neoadjuvant chemotherapy improved pathological prognostic factors in patients with stage IIB cervical cancer, it was not sufficiently effective to decrease adjuvant therapy. Neoadjuvant chemotherapy also did not improve the rate of patient survival compared to the rate of patient survival in the radiation therapy group.


Sign in / Sign up

Export Citation Format

Share Document